Spruce Biosciences Inc (SPRB)
$0.55
+0.03
(+5.97%)▲
Live
Performance
- $0.51$0.57$0.55
6.95%
Downside
Day's Volatility :9.5%
Upside
2.74%
- $0.41$5.95$0.55
25.25%
Downside
52 Weeks Volatility :93.09%
Upside
90.76%
Returns
| Period | Spruce Biosciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -1.18% | 3.6% | 0.0% |
6 Months | -25.0% | 10.2% | 0.0% |
1 Year | -54.47% | 19.6% | 0.0% |
3 Years | -88.59% | 16.8% | -23.0% |
Highlights
Market Capitalization | 21.1M |
Book Value | $1.43 |
Earnings Per Share (EPS) | -1.04 |
Wall Street Target Price | 2.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -623.35% |
Return On Assets TTM | -29.46% |
Return On Equity TTM | -55.37% |
Revenue TTM | 9.6M |
Revenue Per Share TTM | 0.23 |
Quarterly Revenue Growth YOY | -25.6% |
Gross Profit TTM | 0.0 |
EBITDA | -47.4M |
Diluted Eps TTM | -1.04 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.99 |
EPS Estimate Next Year | -0.93 |
EPS Estimate Current Quarter | -0.32 |
EPS Estimate Next Quarter | -0.31 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 354.55%
Technicals Summary
Sell
Neutral
Buy
Spruce Biosciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Spruce Biosciences Inc | 21.83% | -25.0% | -54.47% | -88.59% | -96.95% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Spruce Biosciences Inc | NA | NA | NA | -0.99 | -0.55 | -0.29 | NA | 1.43 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Spruce Biosciences Inc | Buy | $21.1M | -96.95% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Spruce Biosciences Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 138.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 133.4%
Institutional Holdings
RiverVest Venture Management LLC
7.11%The Carlyle Group Inc
7.01%Rock Springs Capital Management LP
6.32%Rosalind Advisors, Inc.
3.65%Vanguard Group Inc
2.09%Altium Capital Management, LP
1.96%
Company Information
spruce biosciences is a clinical stage biopharmaceutical company focused on developing novel therapies for rare diseases affecting the endocrine system.
Organization | Spruce Biosciences Inc |
Employees | 22 |
CEO | Mr. Michael G. Grey |
Industry | Commercial Services |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$0.55
+5.97%
Invesco Bulletshares 2025 Hi
$0.55
+5.97%
Schwab International Dividend Equity Etf
$0.55
+5.97%
Blockchain Coinvestors Acquisition Corp.
$0.55
+5.97%
Allgiant Travel Company
$0.55
+5.97%
Rogers Corp
$0.55
+5.97%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$0.55
+5.97%
Iheartmedia
$0.55
+5.97%
Lightpath Technologies Inc
$0.55
+5.97%